Praxis Medica
Sign in
Issue image

More articles from Volume 34, Issue 2, 2006

EHOCARDIOGRAPHIC CHARACTERISTICS OF LEFT VENTRICLE IN NON-Q ACUTE MYOCARDIAL INFARCTION

VITAMIN C CONCENTRATIONS IN SERUM BEETWEN PATIENTS SUFFERING FROM DIFFERENT FORMS OF NON-SPECIFIC OSTEOMYELITIS

QUALITY QUALITY AND EFFICACY AND EFFICACY OF A TELECOLPOSCOPY TELECOLPOSCOPY PROGRAMME PROGRAMME

RECURENT ECURENT CHILDREN HEADACHES IN CHILDREN HEADACHES IN VOJVODINA

PREGNANCY TERMINATION AT PRENATALLY DIAGNOSTIFIED FETAL ANOMALY: TWO PROTOCOL COMPARATION

THE USE OF THE USE OF ANTITUBERCULOSIS DRUGS (A ANTITUBERCULOSIS DRUGS (ATD) TODAY

J. Rašić ,
J. Rašić

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

View authors publications

Search this author on:

PubMed | Google Scholar
S. Janićijević-Hudomal ,
S. Janićijević-Hudomal

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

View authors publications

Search this author on:

PubMed | Google Scholar
D. Radišić ,
D. Radišić

Internal clinic, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

View authors publications

Search this author on:

PubMed | Google Scholar
Z. Bukumirić ,
Z. Bukumirić

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

View authors publications

Search this author on:

PubMed | Google Scholar
Z. Stanojević
Z. Stanojević

Institute of Pharmacology and toxicology, Medical Faculty Priština , Kosovska Mitrovica , Kosovo*

View authors publications

Search this author on:

PubMed | Google Scholar

Published: 01.12.2006.

Volume 34, Issue 2 (2006)

pp. 63-68;

https://doi.org/10.70949/pramed200602159R

Abstract

The World Health Organization (WHO) declared tuberculosis (TB) a global emergensy in recognition of its growing importance as public health problem. In response to this situation WHO in 1990 was developed new strategy and framework for effective TB control, wich was called „DOTS“. The aims of treatment of TB are: to cure the pation of TB, to prevent death from active TB or its late effects, to prevent relapse of TB, to decrease transmission of TB to others, and to prevent
the development of acqured drug resistance. Antituberculosis drugs (ATD) are antibiotics and synthetic drugs used in the
treatment of tuberculosis and other deases caused by microorganisms of the genus Mycobacterium. The essential ATD are:
isoniazid (H), rifampicin (R), pyrazinamid (Z), streptomycin (S), ethambutol (E), and thioacetazone (T). The reserve ATD
are: amikacin (Am), kanamycin (Km), capreomycin (Cm), ciprofloxacin (Cx), ofloksacin (O), cycloserine (Cs), ethionamide (Et), protionamide (Pt), and p-aminosalycilic acid (PAS). The regimen recommended for each patient depends on the
diagnostic category for each patient. There are several possible regimens. ATB treatment regimens consists of two phases:
an initial phase and a continuation phase

Keywords

Tuberculosis (TB),

The antituberculosis drugs (ATD),

TB treatment regimens

References

1.
T.L P. Tuberculosis. JAMA. 291(1266).
2.
K. T, T. T, T. S, G. A, A. K, L. K, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 345:170–4.
3.
McCarthy M. Experts see progress in fight against tuberculosis. Lancet. 359(9322).
4.
P.G. S, K. F, J. P, E. A, E. R, G. R, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 359(9322):1980–9.
5.
T.L P. Timebomb: The global epidemic of multi-drug resistant tuberculosis. JAMA. 287:780–1.
6.
K.M. CT, J.F. D, W.A. G, Altena R., Wert T.S., A. PM, et al. Antituberculosis-drug resistance. N Engl J Med. 339:1079–80.
7.
Stephenson J. Multidrug-resistant TB. JAMA. 291(1826).
8.
P. P, A V. Treatment of tuberculosis meningitis: role of short-course chemotherapy. Quarterly Journal of Medicine. 62(239):249–58.
9.
Loenhout-Rooyackers J.H. Tuberculosis meningitis: is a 6-month treatment regimen sufficient? Int J Tub Lung Dis. 5(11):1028–35.
10.
S.W. D, W.R. J, W.J M. Multidrug-resistant tuberculosis. Ann Intern Med. 117:257–9.
11.
M.A. E, A. L, L. S, F. B, S.J. K, A. R, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med. 344(17):1294–303.
12.
H.L R. Interventions for Tuberculosis Control and Elimination.
13.
J. C, N. H, F M. Clinical Tuberculosis.
14.
Organization WH. Essential Medicines: WHO Model List (Revised April 2002.
15.
Centers for Disease Control and Prevention. Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR. 52(No RR-11):1–77.
16.
H.F C. Antimycobacterial drugs. In: Basic and Clinical Pharmacology.
17.
Organization WH. Treatment of Tuberculosis: Guidelines for National Programmes.
18.
W.H.O./I.U.A.T.L.D./K.N.C.V. Revised international definitions in tuberculosis control. Int J Tub Lung Dis. 5(3):213–5.
19.
A. P, P C. Tuberculosis Handbook. World Health Organization.
20.
K. S, O. O, R.G. B, F. G, I. A, J B. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med. 353:1008–20.
21.
C. D, G.P. G, K. S, B.G W. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet. 352(9144):1886–91.
22.
Popovac D. Bolesti pluća.
23.
Organization WH. Global Tuberculosis Control.
24.
Organization WH. An Expanded DOTS Framework for Effective Tuberculosis Control.
25.
Centers for Disease Control and Prevention. Trends in tuberculosis United States, 2004. JAMA. 293:2205–7.
26.
Organization WH. Global Tuberculosis Control.
27.
Agelis C.D., A F. Tuberculosis—a global problem requiring a global solution. JAMA. 293:2793–4.
28.
E.L. C, C.J. W, N. W, D. M, B.G. W, M.C. R, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 163:1009–21.
29.
Stephenson J. Global TB/HIV crisis. JAMA. 290(740).
30.
Ahlburg D. The Economic Impacts of Tuberculosis.
31.
C. D, D.M. B, M.S. H, M.C R. Evolution of tuberculosis control and prospect for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 293:2767–75.

Citation

Copyright

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by
DOAJ
Google Scholar
ERIHPLUS
MIAR I
Crossref